Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of single-dose QP-6211 for post-hemorrhoidectomy analgesia
ChiCTR2400092253Phase 2Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QP-6211 in postoperative pain (4 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoint: NRS pain intensity score. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
QP-6211
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2400092253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092253.